Biomarkers for prostate cancer

Journal of Cellular Biochemistry

Volumn 108, Issue 1, 2009, Pages 3-9

  Leman, Eddy S ^a   Getzenberg, Robert H ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Biomarkers; Prostate cancer; PSA

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; BIOLOGICAL MARKER; EARLY PROSTATE CANCER ANTIGEN; EARLY PROSTATE CANCER ANTIGEN 2; ENDOGLIN; GLYCEROPHOSPHOINOSITOL INOSITOLPHOSPHODIESTERASE; NUCLEAR MATRIX PROTEIN 48; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG;

CANCER SCREENING; DIAGNOSTIC VALUE; EARLY CANCER; EARLY DIAGNOSIS; GENE; HUMAN; NUCLEIC ACID ANALYSIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEOMICS; REVIEW; UROC28 GENE;

ANIMALS; ANNEXIN A3; ANTIGENS, NEOPLASM; HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RACEMASES AND EPIMERASES; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 69249141452     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.22227     Document Type: Review

References (51)

1. American Cancer Society. 2009. Cancer Facts & Figures. 4.
2. An G, Ng AY, Meka CS, Luo G, Bright SP, Cazares L, Wright GL, Jr., Veltri RW. 2000. Cloning and characterization of UROC28, a novel gene overexpressed in prostate, breast, and bladder cancers. Cancer Res 60:7014-7020.
3. Barry MJ. 2001. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 344:1373-1377.
4. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, Debruyne FM, Ru N, Isaacs WB. 1999. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59:5975-5979.
5. Byrne JC, Downes MR, O'Donoghue N, O'Keane C, O'Neill A, Fan Y, Fitzpatrick JM, Dunn M, Watson RW. 2009. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 8:942-957.
6. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, Walsh PC. 1992. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267:2215-2220.
7. Catalona WJ, Smith DS, Ornstein DK. 1997. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA 277:1452-1455.
8. Chen Z, Fan Z, McNeal JE, Nolley R, Caldwell MC, Mahadevappa M, Zhang Z, Warrington JA, Stamey TA. 2003. Hepsin and maspin are inversely expressed in laser capture microdissectioned prostate cancer. J Urol 169:1316-1319.
9. Constantinou J, Feneley MR. 2006. PSA testing: An evolving relationship with prostate cancer screening. Prostate Cancer Prostatic Dis 9:6-13.
10. Cooner WH, Mosley BR, Rutherford CL, Jr., Beard JH, Pond HS, Terry WJ, Igel TC, Kidd DD. 1990. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 143:1146-1152; discussion 1152-1154.
11. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW, Schalken JA. 2002. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62:2695-2698.
12. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, Ellis WJ, Marks LS, Fradet Y, Rittenhouse H, Groskopf J. 2008. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 179:1587-1592.
13. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM. 2001. Delineation of prognostic biomarkers in prostate cancer. Nature 412:822-826.
14. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. 2004. Early identification of individuals with prostate cancer in negative biopsies. J Urol 171:1419-1423.
15. Diaz JI, Cazares LH, Semmes OJ. 2008. Tissue sample collection for proteomics analysis. Methods Mol Biol 428:43-53.
16. Ferro MA, Barnes I, Roberts JB, Smith PJ. 1987. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol 60:69-73.
17. Fujita K, Ewing CM, Chan DY, Mangold LA, Partin AW, Isaacs WB, Pavlovich CP. 2009. Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 124:664-669.
18. Getzenberg RH, Abrahamsson PA, Canto EI, Chinnaiyan AM, Djavan B, Laxman B, Ogawa O, Slawin K, Tomlins SA, Yu J. 2006. Advances in biomarkers for prostate diseases. In: McConnell J, Denis L, Akaza H, Khoury S, Schalken J, editors. Prostate cancer. Editions 21. Paris, France: Health Publications. p. 85-146.
19. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, Brentano S, Mathis J, Pham J, Meyer T, Cass M, Hodge P, Macairan ML, Marks LS, Rittenhouse H. 2006. APTIMA PCA3 molecular urine test: Development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52:1089-1095.
20. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, Netto GJ. 2007. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 177:1736-1740.
21. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. 2003. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44: 8-15 discussion 15-6.
22. Hlavaty JJ, Partin AW, Shue MJ, Mangold LA, Derby J, Javier T, Kelley S, Stieg A, Briggman JV, Hass GM, Wu YJ. 2003. Identification and preliminary clinical evaluation of a 50.8-kDa serum marker for prostate cancer. Urology 61:1261-1265.
23. Kollermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C, Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz A. 2008. Expression and prognostic relevance of annexin A3 in prostate cancer. Eur Urol 54:1314-1323.
24. Kotti TJ, Savolainen K, Helander HM, Yagi A, Novikov DK, Kalkkinen N, Conzelmann E, Hiltunen JK, Schmitz W. 2000. In mouse alpha-methylacyl-CoA racemase, the same gene product is simultaneously located in mitochondria and peroxisomes. J Biol Chem 275:20887-20895.
25. Leman ES, Getzenberg RH. 2007. The current state of biomarkers for prostate cancer. In: Feneley M, Payne H, editors. Therapeutic strategies in prostate cancer. Oxford, United Kingdom: Clinical Publishing. p. 25-42.
26. Leman ES, Cannon GW, Trock BJ, Sokoll LJ, Chan DW, Mangold L, Partin AW, Getzenberg RH. 2007. EPCA-2: A highly specific serum marker for prostate cancer. Urology 69:714-720.
27. Leman ES, Magheli A, Cannon GW, Mangold L, Partin AW, Getzenberg RH. 2009. Analysis of a serum test for prostate cancer that detects a second epitope of EPCA-2. Prostate [Epub ahead of print].
28. Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, Ewing CM, Platz EA, Ferdinandusse S, Wanders RJ, Trent JM, Isaacs WB, De Marzo AM. 2002. Alpha-methylacyl-CoA racemase: A new molecular marker for prostate cancer. Cancer Res 62:2220-2226.
29. Malik G, Rojahn E, Ward MD, Gretzer MB, Partin AW, Semmes OJ, Veltri RW. 2007. SELDI protein profiling of dunning R-3327 derived cell lines: Identi-fication of molecular markers of prostate cancer progression. Prostate 67:1565-1575.
30. McLerran D, Grizzle WE, Feng Z, Thompson IM, Bigbee WL, Cazares LH, Chan DW, Dahlgren J, Diaz J, Kagan J, Lin DW, Malik G, Oelschlager D, Partin A, Randolph TW, Sokoll L, Srivastava S, Srivastava S, Thornquist M, Troyer D, Wright GL, Zhang Z, Zhu L, Semmes OJ. 2008. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 54:53-60.
31. M'Koma AE, Blum DL, Norris JL, Koyama T, Billheimer D, Motley S, Ghiassi M, Ferdowsi N, Bhowmick I, Chang SS, Fowke JH, Caprioli RM, Bhowmick NA. 2007. Detection of pre-neoplastic and neoplastic prostate disease by MALDI profiling of urine. Biochem Biophys Res Commun 353:829-834.
32. Potter SR, Partin AW. 1999. Prostate cancer: Detection, staging, and treatment of localized disease. Semin Roentgenol 34:269-283.
33. Punglia RS, D'Amico AV, Catalona WJ, Roehl KA, Kuntz KM. 2003. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med 349:335-342.
34. Rubin MA, Zhou M, Dhanasekaran SM, Varambally S, Barrette TR, Sanda MG, Pienta KJ, Ghosh D, Chinnaiyan AM. 2002. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 287:1662-1670.
35. Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Ghosh D, Wei JT, Chinnaiyan AM, Adami HO, Kantoff PW, Johansson JE. 2005. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 14:1424-1432.
36. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, Blase A, Koo S, Sarno M, Rittenhouse H, Groskopf J, Vessella RL. 2008. A multicenter evaluation of the PCA3 molecular urine test: Pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 389:1-6.
37. Sreekumar A, Laxman B, Rhodes DR, Bhagavathula S, Harwood J, Giacherio D, Ghosh D, Sanda MG, Rubin MA, Chinnaiyan AM. 2004. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer. J Natl Cancer Inst 96:834-843.
38. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lonigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sundaram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. 2009.
39. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457:910-914.
40. Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA, Diamandis EP. 2004. Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. J Urol 171:187-191.
41. Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. 2008. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 14:3362-3366.
42. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF. 2009. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69:886-894.
43. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA, Jr. 2004. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med 350:2239-2246.
44. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, Crowley JJ, Parnes HL, Coltman CA, Jr. 2005. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. JAMA 294:66-70.
45. Tinzl M, Marberger M, Horvath S, Chypre C. 2004. DD3PCA3 RNA analysis in urine - A new perspective for detecting prostate cancer. Eur Urol 46:182-186; discussion 187. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. 2005. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 174:514-518.
46. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, Witjes JA, Cornel EB, Karthaus HF, Smits GA, Dijkman GA, Mulders PF, Schalken JA. 2007. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination; a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res 13:939-943.
47. van Gils MP, Hessels D, Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, Rittenhouse HG, Schalken JA. 2008. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 68:1215-1222.
48. Welsh JB, Sapinoso LM, Su AI, Kern SG, Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr, Hampton GM. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61:5974-5978.
49. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, Petrovics G, Ibrahim M, Elsamanoudi S, Cullen J, Sesterhenn IA, Brassell S, Rittenhouse H, Srivastava S, McLeod DG. 2008. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol 180:1975-1978; discussion 1978-1979.
50. Wozny W, Schroer K, Schwall GP, Poznanovic S, Stegmann W, Dietz K, Rogatsch H, Schaefer G, Huebl H, Klocker H, Schrattenholz A, Cahill MA. 2007. Differential radioactive quantification of protein abundance ratios between benign and malignant prostate tissues: Cancer association of annexin A3. Proteomics 7:313-322.
51. Zielie PJ, Mobley JA, Ebb RG, Jiang Z, Blute RD, Ho SM. 2004. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions. J Urol 172:1130-1133.